The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies

Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels

(2014) A. M. Gomes et al.   HAEMATOLOGICA

The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models

(2014) Amancio Carnero et al.   Frontiers in Oncology

Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K/Akt pathway in adult acute leukemia

(2013) Fang-Fang Huang et al.   CANCER LETTERS

Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity

(2013) Laura Quotti Tubi et al.   Journal of Hematology & Oncology

Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia

(2013) L R Martins et al.   LEUKEMIA

CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway

(2013) R C Prins et al.   LEUKEMIA

Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling

(2013) F Buontempo et al.   LEUKEMIA

Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: Biochemical evidence and therapeutic perspectives

(2013) Christian Borgo et al.   Molecular Oncology

Protein Kinase CK2 Inhibition Down Modulates the NF-κB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells

(2013) Sabrina Manni et al.   PLoS One

Druggability of the CK2 inhibitor CX-4945 as an anticancer drug and beyond

(2012) Jiyeon Kim et al.   ARCHIVES OF PHARMACAL RESEARCH

Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways

(2012) F Piazza et al.   LEUKEMIA

Src, Akt, NF-κB, BCL-2 and c-IAP1 may be involved in an anti-apoptotic effect in patients with BCR-ABL positive and BCR-ABL negative acute lymphoblastic leukemia

(2012) José E. Vázquez-Franco et al.   LEUKEMIA RESEARCH

Update on Therapy of Chronic Lymphocytic Leukemia

(2011) John G. Gribben et al.   JOURNAL OF CLINICAL ONCOLOGY

On CK2 regulation of chronic lymphocytic leukemia cell viability

(2011) Leila R. Martins et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer

(2011) Fabrice Pierre et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia

(2010) L. R. Martins et al.   BLOOD

CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy

(2010) A. Siddiqui-Jain et al.   CANCER RESEARCH

Structural basis of CX-4945 binding to human protein kinase CK2

(2010) Andrew D. Ferguson et al.   FEBS LETTERS

Discovery and SAR of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer

(2010) Fabrice Pierre et al.   JOURNAL OF MEDICINAL CHEMISTRY

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

(2010) L. A. Honigberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Addiction to protein kinase CK2: A common denominator of diverse cancer cells?

(2009) Maria Ruzzene et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Protein Kinase CK2 in Health and Disease

(2009) I. Dominguez et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Protein Kinase CK2 in Health and Disease

(2009) J. H. Trembley et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis

(2008) B. Shor et al.   CANCER RESEARCH

PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability

(2008) Ana Silva et al.   JOURNAL OF CLINICAL INVESTIGATION

Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy

(2008) S Faderl et al.   LEUKEMIA

Gene targeting of CK2 catalytic subunits

(2008) David C. Seldin et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY